Personalized maintenance therapy for multiple myeloma after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a personalized approach to maintenance therapy for people with multiple myeloma who have already had a stem cell transplant. Your treatment plan may be adjusted based on how well your cancer responds and on certain risk factors, with the goal of keeping you in remission longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma and had at least 4 rounds of initial treatment, followed by high-dose chemotherapy and a stem cell transplant within the past year.
- You have achieved at least a partial response (cancer has shrunk or stopped growing) before starting maintenance therapy.
- You are able to perform daily activities with little or no help (ECOG score 0, 1, or 2).
- Your blood counts are adequate (certain minimum levels of white blood cells, hemoglobin, and platelets).
- You do not have an active infection and your liver and kidney function are within acceptable ranges.
- You have not had a stroke or serious blood clot in the last year, and do not have severe lung disease or uncontrolled asthma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two medicines, iberdomide and daratumumab, given as maintenance therapy after an autologous stem cell transplant. It is for people with multiple myeloma who still have small amounts of cancer cells detected after transplant and who have already been treated with a daratumumab-containing regimen.
This trial tests different dosing schedules of daratumumab to find a more cost-effective option for patients with multiple myeloma who have already had a stem cell transplant and achieved at least a partial response. It aims to see if a lower dose can work just as well.
This trial tests a type of immune therapy called bispecific T-cell redirectors combined with standard medicines for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment helps control the cancer better.
This trial tests whether adding teclistamab to lenalidomide (or using teclistamab alone) helps keep newly diagnosed multiple myeloma from coming back after an autologous stem cell transplant. It’s comparing these options to lenalidomide alone as long-term maintenance.
This trial tests whether a new drug called elranatamab combined with lenalidomide works better than the standard daratumumab/lenalidomide combination as maintenance therapy after a stem cell transplant for newly diagnosed myeloma.
This trial tests combining two drugs, talquetamab and lenalidomide, as maintenance therapy after a stem cell transplant for multiple myeloma. The goal is to see if this combination helps keep the cancer from coming back.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.